Acquired lecithin: CHolesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease

Journal of Internal Medicine

Volumn 277, Issue 5, 2015, Pages 552-561

  Calabresi, L ^a   Simonelli, S ^a   Conca, P ^a   Busnach, G ^b   Cabibbe, M ^b   Gesualdo, L ^c   Gigante, M ^d   Penco, S ^b   Veglia, F ^e   Franceschini, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

HDL; LCAT; Cholesterol esterification; Chronic kidney disease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; APOLIPOPROTEIN;

AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GENDER; HUMAN; HYPERTENSION; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PRIORITY JOURNAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; COMPLICATION; ESTERIFICATION; HYPOALPHALIPOPROTEINEMIAS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

APOLIPOPROTEINS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; ESTERIFICATION; FEMALE; HUMANS; HYPOALPHALIPOPROTEINEMIAS; LECITHIN ACYLTRANSFERASE DEFICIENCY; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TRIGLYCERIDES;

EID: 84927113207     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12290     Document Type: Article

References (35)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-9.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
3. Foster MC, Rawlinngs AM, Marrett E et al. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am Heart J 2013; 166: 150-6.
4. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918-27.
5. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290: F262-72.
6. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res 2005; 46: 154-62.
7. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-8.
8. Pahl MV, Ni Z, Sepassi L, Moradi H, Vaziri ND. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant 2009; 24: 2541-6.
9. Calabresi L, Pisciotta L, Costantin A et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 2005; 25: 1972-8.
10. McLeod R, Reeve CE, Frohlich J. Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1984; 25: 683-8.
11. Miida T, Miyazaki O, Hanyu O et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003; 14: 732-8.
12. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
13. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-69.
14. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000; 148: 387-96.
15. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 2007; 195: 385-91.
16. Favari E, Lee M, Calabresi L et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding Cassette Transporter A1- but not Scavenger Receptor Class B Type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004; 279: 9930-6.
17. Murakami T, Michelagnoli S, Longhi R et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995; 15: 1819-28.
18. Forte TM, Norum KR, Glomset JA, Nichols AV. Plasma lipoproteins in familial lecithin:cholesterol acyltransferase deficiency. Structure of low and high density lipoproteins as revealed by electron microscopy. J Clin Invest 1971; 50: 1141-8.
19. Rye KA, Barter PJ. Regulation of high-density lipoprotein metabolism. Circ Res 2014; 114: 143-56.
20. Rader DJ, Ikewaki K, Duverger N et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994; 93: 321-30.
21. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999; 14: 1462-6.
22. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004; 15: 1008-15.
23. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012; 222: 299-306.
24. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001; 59: 2192-6.
25. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res 2013; 161: 477-85.
26. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009; 153: 77-85.
27. Davit-Spraul A, Therond P, Leroy A et al. Inhibition of lecithin:cholesterol acyltransferase by phosphatidylcholine hydroperoxides. FEBS Lett 1999; 447: 106-10.
28. Barter PJ, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-10.
29. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572-80.
30. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
31. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med 2010; 20: 50-3.
32. Baragetti A, Norata GD, Sarcina C et al. High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 2013; 274: 252-62.
33. Chen Z, Wang SP, Krsmanovic ML et al. Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism 2012; 61: 470-81.
34. Rousset X, Vaisman B, Auerbach B et al. Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 2010; 335: 140-8.
35. Simonelli S, Tinti C, Salvini L et al. Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. Biologicals 2013; 41: 446-9.